Ultimele actualizari :
08/05/2024
Citostatic   Daunorubicin hydrochloride  
Injectabil
Stabilitatea in solutie Stabilitatea in amestec Factorii care influenteaza stabilitatea Compatibilitate Microunde Bibliografie Pdf
   Formula chimica  

Denumirea comerciala   Denumirea comerciala     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Cerubidin Danemarca, Irlanda, Marea Britanie, Norvegia, Suedia
Cerubidine Belgia, Canada, Chilli, Elvetia, Franta, Luxemburg, Maroc, Olanda, SUA, Tunisia, Turcia
D Blastin Maroc
Daunac Columbia
Daunobin India
Daunoblastin Austria, Germania
Daunoblastina Arabia Saudita, Grecia, Iran, Italia, Spania, Ungaria, Venezuela
Daunocin India, Malaezia, Peru
Daunogobbi Argentina
Daunomed India, Peru
Daunomycin India
Daunoplus India
Daunorubicin Australia, Canada, Marea Britanie, Noua Zeelandă, SUA
Daunorubicina Chilli, Columbia, Ecuador, Mexic, Peru
Daunorubitec India
Daunoside India
Daunotec India, Venezuela
Daurocina Chilli
Epodoxo Peru
Maxidauno Argentina, Ecuador
Oncodaunotec Columbia
Rubilem Mexic
Runabicon Columbia, Mexic
Zuleb Mexic
Bibliografie   Injectabil   Bibliografie : Daunorubicin hydrochloride  
Tip Publicare
3 Ziar Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
81 Ziar Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678.
84 Ziar Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
99 Ziar Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
148 Ziar Dine T, Cazin JC, Gressier B, Luycks M, Brunet C, Cazin M, Goudaliez F, Mallevais ML, Toraub I.
Stability and compatibility of four anthracyclines: doxorubicin, epirubicin, daunorubicin and pirarubicin with PVC infusion bags.
Pharm Weekbl [Sci] 1992 ; 14: 365-369.
150 Ziar Aujoulat P, Coze C, Braguer D, Raybaud C.
Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens.
J Pharm Clin 1993 ; 12: 31-35.
152 Ziar Chevrier R, Sautou V, Pinon V, Demecop F, Chopineau J.
Stability and compatibility of a mixture of the anti-cancer drugs etoposide, cytarabine and daunorubicine for infusion.
Pharm Acta Helv 1995 ; 70: 141-148.
169 Ziar Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
244 Ziar Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
249 Ziar Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
307 Ziar Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
334 Ziar Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992.
492 Ziar Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
632 Ziar Beijnen JH, Rosing H, De Vries PA, Underberg WJM.
Stability of anthracycline antitumour agents in infusion fluids.
J Parenter Sci Technol 1985 ; 39: 220-222.
643 Ziar Seargeant LE, Kobrinsky NL, Sus CJ, Nazeravich DR.
In vitro stability and compatibility of daunorubicin, cytarabine, and etoposide.
Cancer Treat Rep 1987 ; 71: 1189-1192.
686 Ziar Wood MJ, Irwin WJ, Scott DK.
Stability of doxorubicin, daunorubicin and epirubicin in plastic syringes and minibags.
J Clin Pharm Ther 1990 ; 15: 279-289.
905 Ziar Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
1265 Ziar Wood MJ, Irwin WJ, Scott DK.
Photodegradation of doxorubicin, daunorubicin and epirubicin measured by high-performance liquid chromatography.
J Clin Pharm Ther 1990 ; 15: 291-300.
1284 Ziar Williams BA, Tritton TR.
Photoinactivation of anthracyclines.
Photochem Photobiol 1981 ; 34: 131-134.
1410 Ziar Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1423 Ziar Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1520 Laborator Etude de stabilité des médicaments en Ecoflac®
B Braun 2001
1625 Ziar Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1897 Ziar Sautou-Miranda V, Brigas F, Thibault M, Chopineau J.
Compatibility of doxorubicin, daunorubicin and epirubicin with low-density polyethylene and polyvinyl chloride, and stability in various conditions of storage.
EJHP 2001 ; 7, 3: 108-115.
1982 Ziar Trissel LA, Ogundele AB.
Compatibility of anidulafungin with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 834-837.
2247 Ziar Chan P, Heatherly K, Kupiec T.C, Trissel L.A.
Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2008 ; 12, 3: 276-278.
3438 Ziar Respaud R, Quenum L, Plichon C, Tournamille J.F, Gyan E, Antier D, Viaud-Massuard M.C.
A stability-indicating, ion-pairing, reversed-phase liquid chromatography method for studies of daunorubicin degradation in i.v. infusion fluids.
J Pharm Biomed Anal 2013 ; 83 : 164-170.
3474 Laborator Fluorouracil - Summary of Product Characteristics
Accord Healthcare Limited 2009
3540 Laborator Heparin sodium - Summary of Product Characteristics.
Wockhardt 2010
3604 Laborator Daunorubicine (Cérubidine®) - Résumé des caractéristiques du produit
Sanofi Aventis France 2012
3668 Laborator Dexamethasone - Summary of Product Characteristics
Hospira 2015

  Mentions Légales